

Supporting Information

for Adv. Healthcare Mater., DOI 10.1002/adhm.202300941

All-in-One Heptamethine Cyanine Amphiphiles for Dual Imaging-Guided Chemo-Photodynamic-Photothermal Therapy of Breast Cancer

Yu Li, Jing Zhang, Lijun Zhu, Mou Jiang, Changsheng Ke, Hanxiong Long, Ruoyun Lin, Chaohui Ye, Xin Zhou, Zhong-Xing Jiang* and Shizhen Chen*

Supporting Information

All-in-One Heptamethine Cyanine Amphiphiles for Dual Imaging-Guided Chemo-Photodynamic-Photothermal Therapy of Breast Cancer

Yu Li,[†] Jing Zhang,[†] Lijun Zhu, Mou Jiang, Changsheng Ke, Hanxiong Long, Ruoyun Lin, Chaohui Ye, Xin Zhou, Shizhen Chen^{*} and Zhong-Xing Jiang^{*}

Dr. Y. Li, Mr. M. Jiang, Prof. C. Ye, Prof. X. Zhou, Prof. S. Chen, and Prof. Z.-X. Jiang State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, National Center for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences-Wuhan National Laboratory for Optoelectronics, Wuhan 430071, China. University of Chinese Academy of Sciences, Beijing 100049, China E-mail: chenshizhen@apm.ac.cn (S. Chen) and zxjiang@apm.ac.cn (Z.-X. Jiang)

Dr. J. Zhang School of Life Science and Engineering, Lanzhou University of Technology, Lanzhou 730050, China

Mr. L. Zhu, Mr. C. Ke, Mr. H. Long, Ms. R. Lin School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China

Prof. Z.-X. Jiang

Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China

Prof. C. Ye, Prof. X. Zhou, Prof. S. Chen Optics Valley Laboratory, Hubei 430074, China.

[†]Y. Li and J. Zhang contributed equally to this work.

Table of Contents

1. General Information	2
2. Synthesis of Compounds	
3. ¹⁹ F NMR Spectra of PEG-Cy-F ₉ , PEG-Cy-F ₁₈ and F-oil	
4. In vitro ¹⁹ F MRI Experiments	
5. Optical Properties of PEG-Cy-Fs	
6. CMC and LogP Measurement	
7. Solvent-Dependent ¹⁹ F NMR and TEM Image of PEG-Cy-F ₉	
8. Characterization of Nanoemulsions	
9. Celluar Uptake of SoFoTm/PEG-Cy-F ₁₈ NPs	
10. Detection of Singlet Oxygen	
11. H&E Staining Assay of Major Organs	
12. Copies of ${}^{1}\text{H}/{}^{13}\text{C}/{}^{19}\text{F}$ NMR and MS spectra of compounds	

1. General Information

Unless otherwise indicated, all reagents were obtained from commercial supplier and used without prior purification. Column flash chromatography was performed on silica gel (200-300 mesh) with the eluent as indicated in procedures. ¹H, ¹⁹F and ¹³C NMR spectra were recorded on a Bruker 400 MHz. Chemical shifts are in ppm and coupling constants (*J*) are in Hertz (Hz). ¹H NMR spectra were referenced to tetramethylsilane (d, 0.00 ppm) using CDCl₃ as solvent, ¹³C NMR spectra were referenced to solvent carbons (77.16 ppm for CDCl₃). ¹⁹F NMR spectra were referenced to 2% perfluorobenzene (s, -164.90 ppm) in CDCl₃ or 2% sodium triflate (s, -79.61 ppm) in D₂O. The splitting patterns for ¹H NMR spectra are denoted as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), b (broad) and combinations thereof. MS spectra were recorded on an Asilent LCMS-1100 spectrometer for compounds below 2,000 Da. MALDI-TOF mass spectra were recorded on a Bruker Ultraflex III TOF/TOF spectrometer.

2. Synthesis of Compounds



Scheme S1. Synthetic route of amphiphiles PEG-Cy-Fs

12-bromododecan-1-ol (4).^[1] To a stirring solution of the 1,12-dodecanediol (9.00 g, 44.48 mmol) in 100 mL of toluene was added HBr 47% (4.83 mL, 88.96 mmol). The reaction was stirred at 110 °C for 24 h. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel with ethyl acetate/petroleum ether (1/15) as eluents to provide compound 4 as a light yellow oil (6.19 g, 52% yield). ¹H NMR (400 MHz, CDCl₃) δ 3.62 (t, *J* = 6.7 Hz, 2H), 3.41 (t, *J* = 6.9 Hz, 2H), 1.85 (dt, *J* = 14.5, 7.0 Hz, 3H), 1.56 (p, *J* = 6.7 Hz, 2H), 1.42 (p, *J* = 7.1 Hz, 2H), 1.34 - 1.28 (m, 14H).

 $\mathsf{HO}[\mathsf{CH}_2]_{12}\mathsf{OC}[\mathsf{CF}_3]_3$

5

12-((1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)propan-2-yl)oxy)dodecan-1-ol (**5**). To a solution of NaOH (9.52 g, 0.17 mol) in H₂O (40 mL) was added perfluoro-tert-butanol (36.40 g, 0.15 mol) at 0 °C. After stirring for 3 h, the reaction mixture was lyophilized and the solid was dissolved in DMF. Then compound **4** (46.66 g, 0.18 mol) was added to the solution, and the reaction was heated to 110 °C. After reacting overnight, H₂O was added to the mixture. The organic phase was separated and purified by flash column chromatography on silica gel with ethyl acetate/petroleum ether (1/20) as eluents to provide compound **5** as a light yellow oil (45.42 g, 70% yield). ¹H NMR (400 MHz, CDCl₃) δ 3.99 (t, *J* = 6.5 Hz, 2H), 3.64 (t, *J* = 6.7 Hz, 2H), 1.67 (dt, *J* = 14.6, 6.6 Hz, 2H), 1.57 (p, *J* = 6.7 Hz, 3H), 1.40 – 1.25 (m, 16H). ¹³C NMR (101 MHz, CDCl₃) δ 120.6 (q, *J* = 293.0 Hz), 79.9 (dd, *J* = 59.1, 29.3 Hz), 70.0, 63.2, 32.9, 29.8, 29.72, 29.67, 29.63, 29.56, 29.3, 25.9, 25.4. ¹⁹F NMR (376 MHz, CDCl₃) δ - 73.57. HRMS (ESI) m/z: [M + Na]⁺ calcd for C₁₆H₂₅F₉NaO₂⁺, 443.1603; found, 443.1613.

 $\mathsf{HO}[\mathsf{CH}_2\mathsf{CH}_2\mathsf{O}]_3[\mathsf{CH}_2]_{12}\mathsf{OC}[\mathsf{CF}_3]_3$

7

24,24,24-trifluoro-23,23-bis(trifluoromethyl)-3,6,9,22-tetraoxatetracosan-1-ol (7). Under an atmosphere of N₂, to a suspension of NaH (8.65 g, 60% in mineral oil, 216.10 mmol) in dry THF (150 mL) was added a solution of compound **5** (45.42 g, 108.05 mmol) in THF (150 mL) at 0 °C, and the mixture was stirred for 30 min. Then a solution of cyclic sulfate (34.40 g, 162.08 mmol) in THF (150 mL) was added and the resulting mixture was stirred overnight at rt. Then, water (3.9 mL) was added and H₂SO₄ was added to adjust the pH to 3.0. The mixture was stirred until hydrolysis was completed. The reaction mixture was neutralized with saturated NaHCO₃ solution, concentrated under vacuum and purified by flash chromatography on silica gel with ethyl acetate/petroleum ether (1/8) as eluents to provide

compound **7** as a clear oil (56.29 g, 94% yield). ¹H NMR (400 MHz, CDCl₃) δ 3.99 (t, J = 6.5 Hz, 2H), 3.77 - 3.71 (m, 2H), 3.71 - 3.64 (m, 6H), 3.60 (dt, J = 9.1, 4.4 Hz, 4H), 3.45 (t, J = 6.8 Hz, 2H), 1.71 - 1.63 (m, 2H), 1.59 (p, J = 7.0 Hz, 2H), 1.40 - 1.25 (m, 16H). ¹³C NMR (101 MHz, CDCl₃) δ 120.5 (q, J = 293.0 Hz), 79.4 - 80.3 (m), 72.7, 71.7, 70.69, 70.68, 70.4, 70.1, 70.0, 61.8, 29.8, 29.7, 29.63, 29.59, 29.56, 29.5, 29.2, 26.2, 25.4. ¹⁹F NMR (376 MHz, CDCl₃) δ -73.54. HRMS (ESI) m/z: [M + K]⁺ calcd for C₂₂H₃₇F₉KO₅⁺, 591.2129; found, 591.2127.

N₃[CH₂CH₂O]₃[CH₂]₁₂OC[CF₃]₃

8

1-azido-24,24,24-trifluoro-23,23-bis(trifluoromethyl)-3,6,9,22-tetraoxatetracosane (8). To a solution of compound 7 (20.30 g, 36.74 mmol) in THF (100 mL) was added a solution of NaOH (5.14 g, 128.59 mmol) in water (16 mL). After the solution cooled to 0 °C, a solution of p-toluenesulfonyl chloride (8.41 g, 44.09 mmol) in THF (50 mL) was slowly added, and the resulting mixture was stirred overnight at rt. The reaction mixture was concentrated under vacuum. The residue was dissolved in water (100 mL) and extracted with DCM. The organic layers were concentrated under vacuum to provide crude sulfonate as light yellow oil. To a solution of crude sulfonate in DMF (120 mL) was added NaN₃ (3.58 g, 55.07 mmol), and the resulting mixture was stirred at 80 °C for 12 h. Then, the reaction mixture containing excess NaN₃ was filtered through a pad of Celite, the filtrate was concentrated under vacuum. The residue was dissolved in water (100 mL), and extracted with DCM. The combined organic layers were dried over anhydrous Na₂SO₄, concentrated under vacuum, and purified by flash chromatography on silica gel with ethyl acetate/petroleum ether (1/20) as eluents to obtain compound **8** as a light yellow oil (18.47 g, 87% yield). ¹H NMR (400 MHz, CDCl₃) δ 3.99 (t, J = 6.5 Hz, 2H), 3.71 - 3.64 (m, 8H), 3.59 (dd, J = 5.7, 3.4 Hz, 2H), 3.45 (t, J = 6.8 Hz, 2H), 3.40 (t, J = 5.1 Hz, 2H), 1.71 - 1.63 (m, 2H), 1.58 (p, J = 6.9 Hz, 2H), 1.39 - 1.24 (m, 16H). ¹³C NMR (101 MHz, CDCl₃) δ 120.6 (q, J = 292.8 Hz), 79.5 – 80.4 (m), 71.7, 70.9, 70.8, 70.19, 70.17, 70.0, 50.8, 29.82, 29.76, 29.70, 29.67, 29.63, 29.61, 29.55, 29.3, 26.2, 25.4. ¹⁹F NMR (376 MHz, CDCl₃) δ -73.60. HRMS (ESI) m/z: $[M + K]^+$ calcd for C₂₂H₃₆F₉N₃KO₄⁺, 616.2194; found, 616.2191.

 $NH_{2}[CH_{2}CH_{2}O]_{3}[CH_{2}]_{12}OC[CF_{3}]_{3}$

9

24,24,24-trifluoro-23,23-bis(trifluoromethyl)-3,6,9,22-tetraoxatetracosan-1-amine (9). To a solution of compound 8 (2 g, 3.46 mmol) in THF (20 mL) was added triphenylphosphine (1.36 g, 5.18 mmol), and the resulting mixture was stirred for 1 h at 40 °C. Then H₂O (0.31

mL, 17.2 mmol) was added and the reaction mixture was stirred overnight at this temperature. The solution was concentrated and purified by flash chromatography on silica gel with MeOH/DCM (1/10) as eluents to provide compound **9** as a light yellow oil (1.89 g, 99% yield). ¹H NMR (400 MHz, CDCl₃) δ 3.99 (t, J = 6.4 Hz, 2H), 3.69 – 3.61 (m, 6H), 3.61 – 3.55 (m, 2H), 3.53 (t, J = 5.1 Hz, 2H), 3.45 (t, J = 6.8 Hz, 2H), 2.88 (t, J = 5.1 Hz, 2H), 1.72 – 1.62 (m, 2H), 1.58 (p, J = 6.9 Hz, 2H), 1.39 – 1.25 (m, 16H). ¹³C NMR (101 MHz, CDCl₃) 120.5 (q, J = 293.9 Hz), 79.1 – 80.0 (m), 73.1, 71.6, 70.7, 70.6, 70.3, 70.1, 69.9, 41.7, 29.8, 29.68, 29.66, 29.63, 29.58, 29.56, 29.5, 29.2, 26.2, 25.4. ¹⁹F NMR (376 MHz, CDCl₃) δ - 73.60. HRMS (ESI) m/z: [M + Na]⁺ calcd for C₂₂H₃₈F₉NNaO₄⁺, 574.2549; found, 574.2487.

[CH₂CH₂O]₃[CH₂]₁₂OC[CF₃]₃ HN [CH₂CH₂O]₃[CH₂]₁₂OC[CF₃]₃

10

bis(24,24,24-trifluoro-23,23-bis(trifluoromethyl)-3,6,9,22-tetraoxatetracosyl)amine (10). Under an atmosphere of H₂, a mixture of compound **8** (6.00 g, 10.39 mmol) and Pd/C (10% on carbon, 2.21 g, 2.08 mmol) in dry MeOH (207 mL) was stirred at rt overnight. The mixture was filtrated through a pad of Celite, and the filtrate was concentrated. The residue was purified by column chromatography on silica gel to give product **10** as a light yellow oil (4.92 g, 87% yield) with MeOH/DCM (1/40) as eluents. ¹H NMR (400 MHz, CDCl₃) δ 3.99 (t, *J* = 6.5 Hz, 4H), 3.71 – 3.54 (m, 20H), 3.45 (t, *J* = 6.8 Hz, 4H), 2.86 (t, *J* = 5.3 Hz, 4H), 1.67 (p, *J* = 6.6 Hz, 4H), 1.58 (p, *J* = 6.9 Hz, 4H), 1.39 – 1.24 (m, 32H). ¹³C NMR (101 MHz, CDCl₃) δ 120.5 (q, *J* = 293.0 Hz), 79.4 – 80.3 (m), 71.6, 70.7, 70.6, 70.4, 70.2, 70.1, 70.0, 49.2, 29.8, 29.71, 29.66, 29.63, 29.59, 29.57, 29.5, 29.2, 26.2, 25.4. ¹⁹F NMR (376 MHz, CDCl₃) δ - 73.55, -164.90. HRMS (ESI) m/z: [M + Na]⁺ calcd for C₄₄H₇₃F₁₈N₃NaO₈⁺, 1108.4941; found, 1108.4943.

Me[OCH₂CH₂]₁₁N₃ 12

34-azido-2,5,8,11,14,17,20,23,26,29,32-undecaoxatetratriacontane (12). Compound 12 was obtained from compound 11 as a light yellow oil in 84% yield (6.09 g) by employing the same synthetic procedures as compound **8**. ¹H NMR (400 MHz, CDCl₃) δ 3.64 – 3.54 (m, 40H), 3.50 – 3.46 (m, 2H), 3.33 (q, *J* = 5.1 Hz, 2H), 3.31 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 71.8, 70.58, 70.56, 70.52, 70.46, 70.4, 70.0, 59.0, 50.6. HRMS (ESI) m/z: [M + Na]⁺ calcd for C₂₂H₄₇F₉N₃NaO₁₁⁺, 564.3103; found, 564.3109.

Me[OCH₂CH₂]₁₁NH₂

13

2,5,8,11,14,17,20,23,26,29,32-undecaoxatetratriacontan-34-amine (13). Compound 13 was obtained from compound 12 as a light yellow oil in 85% yield (2.43 g) by employing the same synthetic procedures as compound 9. ¹H NMR (400 MHz, CDCl₃) δ 3.68 – 3.63 (m, 38H), 3.57 – 3.54 (m, 2H), 3.52 (t, *J* = 5.2 Hz, 2H), 3.38 (s, 3H), 2.87 (t, *J* = 5.2 Hz, 2H).



di(2,5,8,11,14,17,20,23,26,29,32-undecaoxatetratriacontan-34-yl)amine (14). Compound 14 was obtained from compound 12 as a light yellow oil in 73% yield (1.36 g) by employing the same synthetic procedures as compound 10. ¹H NMR (400 MHz, CDCl₃) δ 3.70 – 3.59 (m, 80H), 3.57 – 3.54 (m, 4H), 3.38 (s, 6H), 2.86 (t, *J* = 5.3 Hz, 4H). ¹³C NMR (126 MHz, CDCl₃) δ 71.8, 70.4, 70.3, 70.1, 70.0, 58.9, 48.9. HRMS (ESI) m/z: [M + Na]⁺ calcd for C₄₆H₉₅F₉NNaO₂₂⁺,1036.6238; found, 1036.6248.



tert-butyl(S)-27-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-1,1,1-trifluoro-26-oxo-2,2-bis(trifluoromethyl)-3,16,19,22-tetraoxa-25-azatriacontan-30-oate (16). Under an atmosphere of N₂, a solution of Fmoc-L-glutamic acid 5-tert-butyl ester (3.05 g, 7.17 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI·HCl, 1.38 g, 7.17 mmol), and 1-Hydroxybenzotriazole (HOBt, 968.6 mg, 7.17 mmol) in DMF (30 mL) was stirred at rt for 15 min. Then, a solution of compound 9 (2.64 g, 4.78 mmol) in DMF (10 mL) was added and the resulting mixture was stirred for 12 h. The reaction was quenched with water and extracted with DCM three times. The combined organic layers were dried over anhydrous Na₂SO₄, concentrated under vacuum and purified by flash chromatography on silica gel with EA /PE (1/2) as eluents to provide product 16 as a light yellow oil (4.22 g, 92% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.76 (d, J = 7.5 Hz, 2H), 7.60 (d, J = 7.5 Hz, 2H), 7.39 (t, J = 7.4 Hz, 2H), 7.31 (td, J = 7.5, 1.2 Hz, 2H), 5.91 (d, J = 8.0 Hz, 1H), 4.38 (d, J = 7.9 Hz, 10.0 Hz)2H), 4.21 (t, J = 7.2 Hz, 1H), 3.99 (t, J = 6.5 Hz, 2H), 3.64 – 3.54 (m, 10H), 3.50 – 3.39 (m, 4H), 2.45 – 2.25 (m, 2H), 2.11 (q, J = 6.2 Hz, 1H), 1.93 (dd, J = 14.5, 7.2 Hz, 1H), 1.65 (dt, J = 8.2, 6.4 Hz, 2H), 1.56 (p, J = 7.0 Hz, 2H), 1.45 (s, 9H), 1.37 - 1.23 (m, 16H). ¹³C NMR (101 MHz, CDCl₃) δ 172.7, 171.4, 156.2, 143.9, 143.8, 141.3, 127.8, 127.1, 125.2, 120.5 (q, J

= 292.6 Hz, 120.0, 80.8, 79.4 - 80.2 (m), 71.6, 70.5, 70.3, 70.0, 69.9, 69.7, 67.0, 54.3, 47.2, 39.4, 31.6, 29.74, 29.67, 29.63, 29.60, 29.58, 29.55, 29.53, 29.48, 29.2, 28.5, 28.1, 26.1, 25.3. HRMS (ESI) m/z: [M + Na]⁺ calcd for C₄₆H₆₃F₉N₂NaO₉⁺, 981.4282; found, 981.4296.



17

tetraoxatetracosyl)-2,2-bis(trifluoromethyl)-3,16,19,22-tetraoxa-25-azatriacontan-30-

oate (17). Compound 17 was obtained from compound 10 as a light yellow oil in 72% yield (3.70 g) by employing the same synthetic procedures as compound 16. ¹H NMR (400 MHz, CDCl₃) δ 7.76 (d, *J* = 7.5 Hz, 2H), 7.61 (dd, *J* = 7.5, 2.8 Hz, 2H), 7.40 (tt, *J* = 7.5, 1.5 Hz, 2H), 7.32 (tdd, *J* = 7.4, 2.7, 1.2 Hz, 2H), 5.73 (d, *J* = 8.6 Hz, 1H), 4.82 – 4.72 (m, 1H), 4.43 – 4.28 (m, 2H), 4.21 (t, *J* = 7.2 Hz, 1H), 3.99 (t, *J* = 6.5 Hz, 4H), 3.80 (td, *J* = 10.8, 9.7, 5.6 Hz, 2H), 3.68 – 3.51 (m, 21H), 3.42 (dt, *J* = 11.3, 6.9 Hz, 5H), 2.43 – 2.23 (m, 2H), 2.03 (dt, *J* = 11.5, 3.9 Hz, 1H), 1.78 (dtd, *J* = 14.0, 8.3, 7.8, 5.7 Hz, 1H), 1.71 – 1.62 (m, 4H), 1.61 – 1.52 (m, 4H), 1.45 (s, 9H), 1.39 – 1.33 (m, 4H), 1.31 – 1.24 (m, 28H). ¹³C NMR (101 MHz, CDCl₃) δ 172.4, 172.3, 156.1, 144.0, 143.9, 141.3, 127.7, 127.1, 125.3, 125.2, 120.5 (q, *J* = 291.9 Hz), 120.0, 80.6, 79.1 – 80.0 (m), 71.63, 71.60, 70.8, 70.7, 70.6, 70.54, 70.48, 70.10, 70.07, 69.9, 69.3, 69.1, 67.0, 50.2, 48.4, 47.2, 46.6, 31.0, 29.8, 29.7, 29.65, 29.62, 29.57, 29.5, 29.2, 28.1, 26.1, 25.3. ¹⁹F NMR (376 MHz, CDCl₃) δ -73.61. HRMS (ESI) m/z: [M + Na]⁺ calcd for C₆₈H₉₈F₁₈N₂NaO₁₃⁺,1515.6679; found, 1515.6713.



(9H-fluoren-9-yl)methyl(S)-(65,65,65-trifluoro-36,40-dioxo-64,64-bis(trifluoromet-hyl)-2,5,8,11,14,17,20,23,26,29,32,44,47,50,63-pentadecaoxa-35,41-diazapentahexacontan-39yl)carbamate (18). Compound 16 (521 mg, 0.54 mmol) was dissolved in DCM (6 mL), anisole (0.089 mL, 0.81mmol) and TFA (2 mL) were added and the resulting solution was stirred for 12 h. The reaction mixture was neutralized with saturated NaHCO₃ solution and washed with DCM. The combined aqueous phases were concentrated to give a residue. Then,

the residue and HOBt (88.1 mg, 0.65 mmol) were dissolved in DMF (4 mL), and N,N-Diisopropylcarbodiimide (DIC, 0.10 mL, 0.65 mmol) was added to the mixture under an atmosphere of N₂. After 15 min, a solution of compound **13** (336.1 mg, 0.65 mmol) in DCM (2 mL) was added and the resulting mixture was stirred for 12 h at rt. The reaction was quenched with water and extracted with DCM three times. The combined organic layers were dried over anhydrous Na₂SO₄, concentrated under vacuum, and purified by flash chromatography on silica gel with MeOH/DCM (1/25) as eluents to provide compound 18 as a light yellow oil (601 mg, 79% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.76 (d, J = 7.5 Hz, 2H), 7.62 (d, J = 7.5 Hz, 2H), 7.40 (t, J = 7.4 Hz, 2H), 7.34 – 7.29 (m, 2H), 6.27 (d, J = 7.4 Hz, 1H), 4.36 (dd, J = 7.3, 4.1 Hz, 2H), 4.21 (t, J = 7.1 Hz, 1H), 3.99 (t, J = 6.5 Hz, 2H), 3.66 -3.53 (m, 52H), 3.44 (dt, J = 13.7, 5.8 Hz, 6H), 3.38 (s, 3H), 2.36 -2.22 (m, 2H), 2.06 (td, J= 13.9, 13.0, 6.8 Hz, 2H), 1.71 – 1.62 (m, 2H), 1.59 – 1.52 (m, 2H), 1.38 – 1.33 (m, 2H), 1.30 - 1.24 (m, 16H). ¹³C NMR (101 MHz, CDCl₃) δ 173.0, 171.6, 156.4, 144.0, 143.9, 141.3, 127.8, 127.2, 125.3, 120.5 (g, J = 293.6 Hz), 120.0, 79.4 – 80.3 (m), 72.0, 71.6, 70.64, 70.59, 70.52, 70.48, 70.3, 70.2, 70.0, 69.8, 69.6, 67.0, 59.1, 54.5, 47.2, 39.4, 32.4, 29.8, 29.7, 29.63, 29.59, 29.56, 29.5, 29.2, 26.1, 25.4. ¹⁹F NMR (376 MHz, CDCl₃) δ -73.62. HRMS (ESI) m/z: $[M + Na]^+$ calcd for $C_{65}H_{102}F_9N_3NaO_{19}^+$, 1422.6856; found, 1422.6885.



Amide 19. Amide 19 was obtained from compound 17 as a light yellow oil in 84% yield (2.94 g) by employing the same synthetic procedures as compound 18. ¹H NMR (400 MHz, CDCl₃) δ 7.76 (d, *J* = 7.5 Hz, 2H), 7.61 (dd, *J* = 9.6, 7.5 Hz, 2H), 7.40 (t, *J* = 7.4 Hz, 2H), 7.35 – 7.29 (m, 2H), 5.88 (d, *J* = 8.4 Hz, 1H), 4.81 – 4.64 (m, 1H), 4.30 (qd, *J* = 10.4, 7.4 Hz, 2H), 4.21 (t, *J* = 7.3 Hz, 1H), 3.99 (t, *J* = 6.5 Hz, 4H), 3.68 – 3.49 (m, 110H), 3.42 (dt, *J* = 14.0, 7.0 Hz, 6H), 3.38 (s, 6H), 2.58 – 2.39 (m, 2H), 2.18 – 2.07 (m, 1H), 1.80 – 1.71 (m, 1H), 1.71 – 1.63 (m, 4H), 1.61 – 1.52 (m, 4H), 1.40 – 1.33 (m, 4H), 1.31 – 1.24 (m, 28H). ¹³C NMR (101 MHz, CDCl₃) δ 172.5, 172.3, 156.2, 144.0, 143.8, 141.2, 127.7, 127.1, 125.3, 125.2, 120.4 (q, *J* = 293.5 Hz), 120.0, 79.3 – 80.2 (m), 71.9, 71.6, 71.5, 70.6, 70.5, 70.45, 70.0, 69.8, 69.6, 69.58, 69.2, 69.0, 59.0, 48.6, 48.2, 47.1, 46.6, 46.4, 29.7, 29.6, 29.57, 29.54, 29.49, 29.4, 29.1, 28.9,

26.1, 25.3. ^{19}F NMR (376 MHz, CDCl₃) δ -73.62. MS (MALDI) m/z: $[M + Na]^+$ calcd for $C_{110}H_{183}F_{18}N_3NaO_{34}^+$, 2455.229; found, 2455.126.



(S)-2-amino-N5-(2,5,8,11,14,17,20,23,26,29,32-undecaoxatetratriacontan-34-yl)-N1-(24,24,24-trifluoro-23,23-bis(trifluoromethyl)-3,6,9,22-

tetraoxatetracosyl)pentanediamide (20). In dark, piperidine (0.32 mL, 3.29 mmol) was added to a stirring solution of compound **18** (576 mg, 0.41 mmol) in DCM (7 mL), the resulting mixture was stirred for 12 h. Then, the reaction was quenched with water and extracted with DCM. The combined organic layers were dried over anhydrous Na₂SO₄, concentrated under vacuum and purified by flash chromatography on silica gel with MeOH/DCM (1/20) as eluents to provide product **20** as a light yellow oil (431 mg, 89% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.85 (t, *J* = 5.7 Hz, 1H), 7.44 (t, *J* = 5.6 Hz, 1H), 3.99 (t, *J* = 6.4 Hz, 2H), 3.69 – 3.62 (m, 44H), 3.57 (ddd, *J* = 9.6, 6.0, 4.0 Hz, 8H), 3.49 – 3.41 (m, 7H), 3.38 (s, 3H), 2.35 (dtd, *J* = 28.3, 14.4, 7.0 Hz, 2H), 2.07 (dq, *J* = 13.4, 6.7 Hz, 1H), 1.90 (dq, *J* = 14.2, 7.1 Hz, 1H), 1.72 – 1.63 (m, 2H), 1.58 (p, *J* = 7.0 Hz, 2H), 1.37 (t, *J* = 7.7 Hz, 2H), 1.31 – 1.25 (m, 14H). ¹³C NMR (101 MHz, CDCl₃) δ 174.6, 173.1, 120.4 (q, *J* = 294.7 Hz), 79.0 – 79.9 (m), 71.9, 71.6, 70.5, 70.47, 70.43, 70.40, 70.2, 70.05, 69.96, 69.8, 69.7, 59.0, 54.3, 39.2, 39.0, 32.6, 30.9, 29.7, 29.6, 29.53, 29.48, 29.46, 29.4, 29.1, 26.0, 25.2. ¹⁹F NMR (376 MHz, CDCl₃) δ -73.62. HRMS (ESI) m/z: [M + Na]⁺ calcd for C₅₀H₉₂F₉N₃NaO₁₇⁺, 1200.6175; found, 1200.6208.



Amine 21. Amine 21 was obtained from compound 19 as a light yellow oil in 88% yield (913 mg) by employing the same synthetic procedures as compound 20. ¹H NMR (400 MHz, CDCl₃) δ 3.92 (t, *J* = 6.6 Hz, 4H), 3.61 – 3.47 (m, 111H), 3.37 (td, *J* = 6.9, 1.7 Hz, 5H), 3.31

(s, 6H), 3.29 - 3.23 (m, 1H), 2.72 - 2.57 (m, 1H), 2.45 (dt, J = 16.3, 5.9 Hz, 1H), 1.93 (dt, J = 14.6, 5.7 Hz, 1H), 1.64 - 1.55 (m, 5H), 1.51 (q, J = 6.6 Hz, 4H), 1.31 - 1.18 (m, 32H). ¹³C NMR (101 MHz, CDCl₃) δ 175.4, 172.8, 120.2 (q, J = 293.3 Hz), 79.0 – 80.0 (m), 71.6, 71.3, 70.4, 70.3, 70.1, 69.8, 69.7, 69.6, 69.2, 69.1, 68.9, 58.8, 58.7, 49.9, 48.4, 47.9, 46.0, 29.43, 29.36, 29.3, 29.25, 29.19, 29.17, 28.9, 28.5, 25.8, 25.0, 25.0. ¹⁹F NMR (376 MHz, CDCl₃) δ - 73.59. MS (MALDI) m/z: [M + Na]⁺ calcd for C₉₅H₁₇₃F₁₈N₃NaO₃₂⁺, 2233.161; found, 2233.085.



Fluorinated amphiphile PEG-Cy-F₉. Under an atmosphere of N₂, triethylamine (0.18 mL, 1.27 mmol) was added to a stirring solution of IR-780 iodide (283.1 mg, 0.42 mmol) and the compound 20 (500 mg, 0.42 mmol) in DMF (6 mL). The resulting mixture was stirred for 12 h at 85 °C. Then, the reaction was quenched with water and extracted with DCM. The combined organic layers were dried over anhydrous Na₂SO₄, concentrated under vacuum and purified by flash chromatography on silica gel with MeOH/DCM (1/30) as eluents to provide amphiphile PEG-Cy-F₉ as a blue oil (469 mg, 72% yield). ¹H NMR (400 MHz, CDCl₃) δ 9.02 (s, 1H), 7.87 (d, J = 13.0 Hz, 2H), 7.77 (s, 1H), 7.57 (d, J = 17.0 Hz, 1H), 7.31 – 7.26 (m, 4H), 7.09 (t, J = 7.4 Hz, 2H), 6.89 (d, J = 7.9 Hz, 2H), 5.72 (d, J = 13.0 Hz, 2H), 4.55 (d, J = 8.3Hz, 1H), 3.99 (t, J = 6.5 Hz, 2H), 3.82 (t, J = 7.3 Hz, 3H), 3.71 - 3.51 (m, 56H), 3.42 (t, J = 1.57.1 Hz, 4H), 3.38 (s, 3H), 2.53 - 2.38 (m, 6H), 2.32 (t, J = 7.5 Hz, 1H), 1.83 (q, J = 7.2 Hz, 5H), 1.77 – 1.58 (m, 14H), 1.58 – 1.52 (m, 2H), 1.43 – 1.36 (m, 2H), 1.30 – 1.24 (m, 16H), 1.04 (t, J = 7.4 Hz, 6H). ¹³C NMR (126 MHz, CDCl₃) δ 172.8, 171.5, 169.0, 168.2, 143.0, 140.6, 139.7, 128.1, 123.2, 122.2, 121.8, 120.5 (q, J = 293.6 Hz), 108.8, 95.9, 79.4 – 80.2 (m), 71.9, 71.5, 70.61, 70.57, 70.52, 70.49, 70.21, 70.15, 70.0, 69.9, 69.7, 69.2, 62.9, 59.0, 48.1, 45.0, 39.2, 32.4, 31.9, 31.7, 31.0, 29.7, 29.6, 29.6, 29.6, 29.4, 29.1, 28.5, 28.4, 26.1, 25.3, 25.2, 22.7, 21.6, 20.2, 14.1, 11.8. ¹⁹F NMR (376 MHz, CDCl₃) δ -73.65. HRMS (ESI) m/z: [M]⁺ calcd for C₈₆H₁₃₅F₉N₅O₁₇⁺, 1680.9704; found, 1680.9548.



PEG-Cy-F₁₈

Fluorinated amphiphile PEG-Cy-F₁₈ 2. Amphiphile PEG-Cy-F₁₈ **2** was obtained from compound **21** as a light yellow oil in 70% yield (854 mg) by employing the same synthetic procedures as PEG-Cy-F₉ **1**. ¹H NMR (400 MHz, CDCl₃) δ 7.97 (d, J = 13.0 Hz, 2H), 7.35 – 7.31 (m, 3H), 7.14 (t, J = 7.4 Hz, 2H), 6.99 (d, J = 8.0 Hz, 2H), 6.83 (d, J = 8.9 Hz, 1H), 5.84 (d, J = 13.1 Hz, 2H), 4.97 (s, 1H), 3.99 (t, J = 6.4 Hz, 4H), 3.91 (d, J = 7.4 Hz, 4H), 3.73 – 3.40 (m, 116H), 3.38 (s, 6H), 3.37 (s, 1H), 2.60 (t, J = 7.6 Hz, 2H), 2.41 – 2.32 (m, 5H), 1.85 (p, J = 7.1 Hz, 5H), 1.73 (d, J = 16.0 Hz, 12H), 1.68 – 1.61 (m, 4H), 1.54 (dt, J = 12.2, 6.7 Hz, 4H), 1.41 (d, J = 12.3 Hz, 2H), 1.38 – 1.32 (m, 4H), 1.26 (d, J = 5.5 Hz, 28H), 1.06 (t, J = 7.3 Hz, 6H). ¹³C NMR (126 MHz, CDCl₃) δ 172.6, 172.2, 169.6, 166.9, 142.9, 140.4, 140.1, 128.4, 123.7, 122.1, 122.0, 120.5 (q, J = 293.2 Hz), 109.4, 96.7, 79.4 – 80.1 (m), 71.9, 71.57, 71.55, 70.58, 70.55, 70.5, 70.3, 69.93, 69.90, 59.0, 57.4, 48.8, 48.3, 46.4, 45.2, 29.7, 29.6, 29.6, 29.5, 29.4, 29.4, 29.1, 28.6, 28.4, 28.3, 26.1, 25.3, 24.9, 22.7, 21.7, 20.4, 14.1, 11.7. ¹⁹F NMR (376 MHz, CDCl₃) δ -73.59. MS (MALDI) m/z: [M]⁺ calcd for C₁₃₁H₂₁₆F₁₈N₅O₃₂⁺, 2713.514; found, 2713.426.

3. ¹⁹F NMR Spectra of PEG-Cy-F₉, PEG-Cy-F₁₈ and F-oil



Figure S1. ¹⁹F NMR spectra of PEG-Cy-F₉ (a) and PEG-Cy-F₁₈ (b) in MeOH (Using CF₃SO₃Na in D₂O as the internal standard). ¹⁹F NMR spectra of PEG-Cy-F₁₈, F-oil and their mixture in CDCl₃ (c).

4. In vitro ¹⁹F MRI Experiments

The ¹⁹F magnetic resonance imaging (¹⁹F MRI) experiments were performed on a 400 MHz Bruker BioSpec MRI system. The ¹⁹F *in vitro* images were acquired using a spin-echo pulse sequence, method = RARE, matrix size = 32×32 , SI = 20 mm, FOV = 3.0 cm, TR = 4000 ms, TE = 3.0 ms, scan time = 256 s.



Figure S2. ¹⁹F MRI phantom images (a, concentration of PEG-Cy-F₉ as indicated), the logarithm plot of ¹⁹F signal intensity (SI) versus ¹⁹F concentrations (b) of PEG-Cy-F₉.

5. Optical Properties of PEG-Cy-Fs



Figure S3. UV-Vis absorption spectra (a) and NIR FL emission spectra (b) of PEG-Cy-Fs. Normalized absorption (black) and fluorescence emitting (red) spectra of PEG-Cy-F $_9$ (c).

6. CMC and LogP Measurement

The *n*-octanol/water partition coefficients (LogP) values of PEG-Cy-F₉ and PEG-Cy-F₁₈ were measured following shake-flask method.^[2] The maximum UV absorption (Shimadzu UV-2600 spectrophotometer) was measured and compared with calibration curve to obtain the concentration of the compound. LogP = $Lg[(C_s-C_w)/C_w]$, where C_s and C_w are the

concentrations of the starting water solution and the water phase of the compound, respectively.

The CMCs of PEG-Cy- F_9 and PEG-Cy- F_{18} were detected using pyrene as a fluorescent indicator (excitation wavelength, 334 nm). The ratio of fluorescence intensity at 373 nm and 384 from the pyrene was plotted against the amphiphile concentration to calculate the CMC.



Figure S4. UV-Vis absorption standard curves of PEG-Cy- F_9 (a) and PEG-Cy- F_{18} (b), CMC measument of PEG-Cy- F_9 (c).

7. Solvent-Dependent ¹⁹F NMR and TEM Image of PEG-Cy-F₉



Figure S5. Solvent-dependent ¹⁹F NMR spectra (a), and TEM image (b) of PEG-Cy-F₉.

8. Characterization of Nanoemulsions

8.1. DLS Measurement and TEM of Nanoemulsions

Dynamic light scattering (DLS) measurement was performed to determine the average particle size and zeta potential of nanoparticles using Malvern Zetasizer (Malvern, Nano ZS 90, UK). Data were given as mean \pm standard deviation (SD) based on three independent measurements.

Transmission electron microscopy (TEM, JEM-2100, JEOL, negative staining with phosphotungstic acid at 1%, w/v) was used to observe the morphology of nanoemulsions.

8.2. Encapsulation Efficiency and Drug Loading Content

Encapsulation efficiency (EE%) and drug loading content (DLC%) of nanoemulsions were determined using HPLC (Sunfire C18 column (5 μ m, 4.6 × 250 mm). Briefly, 100 μ L of SoFoTm/PEG-Cy-F₁₈ was diluted with 900 μ L of MeOH, the mixture was sonicated for 20 minutes, centrifuged at 12,000 rpm for 20 minutes, and the tamoxifen content in the supernatant was determined by HPLC as the total tamoxifen content in nanoemulsions (W₁). Meanwhile, 100 μ L of SoFoTm/PEG-Cy-F₁₈ was diluted with H₂O, the sample was transferred to an ultrafiltration centrifuge tube, and centrifuged at 12,000 rpm for 20 min. MeOH was added to dissolve the trapped nanoemulsions, the content of tamoxifen in the MeOH solution was determined by HPLC as the encapsulated tamoxifen content in nanoemulsions (W_o). EE% and DLC% were calculated by equations (1) and (2), respectively. Where W_d is the weight of the nanoemulsions.

 $EE\% = W_o/W_t \times 100\%$ (1) $DLC\% = W_o/W_d \times 100\%$ (2)

9. Celluar Uptake of SoFoTm/PEG-Cy-F₁₈ NPs

MCF-7 cells were co-incubated with SoFoTm/PEG-Cy- F_{18} (PEG-Cy- F_{18} concentration: 4 μ M) at 37 °C for 2, 6, 12, 24 h, respectively. The cellular uptake of SoFoTm/PEG-Cy- F_{18} was studied by laser scanning confocal microscopy (A1R/A1, Nikon). Fluorescent dye DAPI was used as the nucleus dye.

10. Detection of Singlet Oxygen

TEMP was selected as a singlet oxygen capture agent. 190 μ L of SoFoTm/PEG-Cy-F₁₈ (0.5 mM) was irradiated with a laser (750 nm, 1 W cm⁻²) for 120 s. Then, 10 μ L of TEMP (0.1 M) was immediately added to the solution and the mixture was measured by electron spin resonance (ESR).





Figure S6. Fluorescence spectra of the SOSG with **NP9** after photoirradiation at wavelengths of 750 nm at 1 W cm⁻² for 120 s (a, concentration as indicated). ESR spectra of PBS, PBS + laser, **NP9**, **NP9** + laser (b). **NP9**: SoFoTm/PEG-Cy-F₁₈.



11. H&E Staining Assay of Major Organs

Figure S7. H&E staining assay results of major organs, scale bar: 100 µm.

12. Copies of ¹H/¹³C/¹⁹F NMR and MS spectra of compounds.

¹H NMR of compound **4**

WILEY-VCH - 7.29 $\begin{array}{c} -8.8\\ -8.6\\$ 3.64 3.62 3.61 3.61 3.61 3.43 3.43 3.43 3.39 HO[CH₂]₁₂Br ار ا ſſ 2.0 2.0 2.0 ЧЧ 00.7 3.5).0 9.5 9.0 8.5 8.0 6.5 6.0 7.0 5.0 4.5 fl (ppm) 0.5 0.0 -0.5 7.5 5.5 4.0 3.0 2.5

1. 0

¹H NMR of compound **5**



¹³C NMR of compound **5**



HRMS of compound 5



¹H NMR of compound 7 HotoHydryCollicHybyCollicFyb $f = \int_{1}^{1} \int_{1}^$

¹³C NMR of compound 7

HO[CH2CH2O]3[CH2]12OC[CF3]3





¹⁹F NMR of compound 7

H0[CH ₂ CH ₂ O] ₃ [CH ₂] ₁₂ OC[CF ₃] ₃	73.54	164.90

190 170 150 130 110 90 70 50 30 10 -10 -30 -50 -70 -90 -110 -130 -150 -170 -190 fl (ppm)

HRMS of compound 7



¹H NMR of compound **8**



¹³C NMR of compound **8**



¹⁹F NMR of compound **8**

1.ICH.01.01ICH.1.20CICE.1	73.60	164.90
N3LCH2CH2CJ3LCH2J12CCLCF3J3	I	

190 170 150 130 110 90 70 50 30 10 -10 -30 -50 -70 -90 -110 -130 -150 -170 -190 f1 (ppm)

HRMS of compound 8



¹H NMR of compound **9**



¹³C NMR of compound **9**



90 70 50 30 10 -10 -30 -50 -70 -90 -110 -130 -150 -170 -190 -210 -230 -250 -270 -290 f1 (ppm)

HRMS of compound 9



¹H NMR of compound **10**





^{190 170 150 130 110 90 70 50 30 10 -10 -30 -50 -70 -90 -110 -130 -150 -170 -190} f1 (ppm)

HRMS of compound 10



¹H NMR of compound **12**



¹³C NMR of compound **12**



220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 f1 (ppm)



HRMS of compound 13



¹H NMR of compound **14**



¹³C NMR of compound **14**



HRMS of compound 14



¹H NMR of compound **16**



¹³C NMR of compound **16**



¹⁹F NMR of compound **16**



HRMS of compound 16



¹H NMR of compound **17**



¹³C NMR of compound 17



¹⁹F NMR of compound **17**



HRMS of compound 17



¹H NMR of compound **18**

H [CH₂CH₂O]₃[CH₂]₁₂OC[CF₃]₃ NHFmoc 0 HN_[CH2CH2O]11 Me ~~ 11 I ×11/1 1111 ~ ۸Ň. 84 à 10.0 9.5 9.0 8.5 3.0 -0.5 -1.0 8.0 6.5 6.0 5.5 2.5 1.0 0.5 0.0 7.0 7.5

¹³C NMR of compound **18**



¹⁹F NMR of compound **18**



HRMS of compound 18



¹H NMR of compound **19**



¹³C NMR of compound **19**



¹⁹F NMR of compound **19**



HRMS(Maldi) of compound 19



¹H NMR of compound **20**

7, 87 7, 7, 7, 87 7, 7, 7, 48 7, 7, 44 1, 7, 7, 44 1, 7, 7, 44 1, 44, 01 1, 3, 3, 3, 56 1, 3, 3, 56 1, 3, 3, 3, 56 1, 3, 3, 3, 56 1, 3, 3, 3, 56 1, 3, 3, 3, 56 1, 3, 3, 3, 56 1, 3, 3, 3, 56 1, 3, 3, 3, 56 1, 3, 3, 3, 56 1, 3, 3, 3, 56 1, 3, 3, 3, 56 1, 3, 3, 3, 56 1, 3, 3, 3, 56 1, 3, 3, 3, 56 1, 3, 3, 3, 56 1,



¹³C NMR of compound **20**



¹⁹F NMR of compound **20**



HRMS of compound 20



¹H NMR of compound **21**

7.29 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.57 3.3.55 3.3.



¹³C NMR of compound **21**



¹⁹F NMR of compound **21**



HRMS(Maldi) of compound 21



¹H NMR of compound PEG-Cy-F₉

7,885 7,238 7,238 7,7,238 7,7,238 7,7,238 7,7,238 7,7,238 7,7,238 7,239 7,239 7,239 7,239 7,239 7,239 7,239 7,249 7,249 7,255 7,25



¹³C NMR of compound PEG-Cy-F₉





HRMS of compound PEG-Cy-F9



¹H NMR of compound PEG-Cy-F₁₈



¹³C NMR of compound PEG-Cy-F₁₈



¹⁹F NMR of compound PEG-Cy-F₁₈



HRMS(Maldi) of compound PEG-Cy-F₁₈



References

- [1] V. S. Gontijo, P. F. Espuri, R. B. Alves, L. F. de Camargos, F. V. d. Santos, W. A. de Souza Judice, M. J. Marques, R. P. Freitas, *Eur. J. Med. Chem.* 2015, 101, 24.
- [2] L.-G. r. Danielsson, Y.-H. Zhang, *TrAC Trends Anal. Chem.* **1996**, 15, 188.